akari
therapeutics
participate
two
september
virtual
investor
conferences
new
york
london
globe
newswire
akari
therapeutics
plc
nasdaq
aktx
biopharmaceutical
company
focused
innovative
therapeutics
treat
orphan
autoimmune
inflammatory
diseases
complement
leukotriene
systems
implicated
today
announced
clive
richardson
chief
executive
officer
participate
host
investor
meetings
following
upcoming
virtual
investor
conferences
event
wainwright
annual
global
investment
conference
date
tuesday
september
presentation
et
event
oppenheimer
fall
healthcare
life
sciences
medtech
summit
date
wednesday
september
presentation
et
investors
interested
arranging
virtual
meeting
company
management
either
conference
contact
respective
conference
coordinator
live
webcast
subsequent
archived
recording
presentation
available
visiting
events
investor
relations
section
company
website
akari
therapeutics
akari
biopharmaceutical
company
focused
developing
inhibitors
acute
chronic
inflammation
specifically
treatment
rare
orphan
diseases
particular
complement
leukotriene
systems
complement
leukotrienes
together
play
primary
role
disease
progression
akari
lead
drug
candidate
nomacopan
formerly
known
coversin
complement
inhibitor
also
independently
specifically
inhibits
leukotriene
activity
nomacopan
currently
clinically
evaluated
four
target
indications
bullous
pemphigoid
bp
thrombotic
microangiopathy
tma
atopic
keratoconjunctivitis
akc
pneumonia
cautionary
note
regarding
statements
certain
statements
press
release
constitute
statements
within
meaning
private
securities
litigation
reform
act
place
undue
reliance
upon
company
forward
looking
statements
except
required
law
company
undertakes
obligation
revise
update
statements
order
reflect
event
circumstance
may
arise
date
press
release
statements
reflect
current
views
plans
intentions
expectations
strategies
prospects
based
information
currently
available
us
assumptions
made
although
believe
plans
intentions
expectations
strategies
prospects
reflected
suggested
statements
reasonable
give
assurance
plans
intentions
expectations
strategies
attained
achieved
furthermore
actual
results
may
differ
materially
described
statements
affected
variety
risks
factors
beyond
control
risks
uncertainties
company
include
limited
needs
additional
capital
fund
operations
ability
continue
going
concern
uncertainties
cash
flows
inability
meet
working
capital
needs
inability
delay
obtaining
required
regulatory
approvals
nomacopan
product
candidates
may
result
unexpected
cost
expenditures
ability
successfully
develop
nomacopan
treatment
related
pneumonia
successfully
commercialize
product
indication
ability
obtain
orphan
drug
designation
additional
indications
risks
inherent
drug
development
general
risks
specific
development
potential
treatments
related
illnesses
uncertainties
obtaining
successful
clinical
results
nomacopan
product
candidates
unexpected
costs
may
result
therefrom
difficulties
enrolling
patients
clinical
trials
ability
enter
collaborative
licensing
commercial
relationships
terms
commercially
reasonable
us
failure
realize
value
nomacopan
product
candidates
developed
developed
light
inherent
risks
difficulties
involved
successfully
bringing
product
candidates
market
inability
develop
new
product
candidates
support
existing
product
candidates
approval
fda
ema
similar
foreign
regulatory
authorities
competing
superior
products
brought
market
risks
resulting
unforeseen
side
effects
risk
market
nomacopan
may
large
expected
risks
associated
impact
outbreak
coronavirus
risks
associated
sec
investigation
inability
obtain
maintain
enforce
patents
intellectual
property
rights
unexpected
costs
associated
enforcement
litigation
inability
obtain
maintain
commercial
manufacturing
arrangements
third
party
manufacturers
establish
commercial
scale
manufacturing
capabilities
inability
timely
source
adequate
supply
active
pharmaceutical
ingredients
third
party
manufacturers
company
depends
unexpected
cost
increases
pricing
pressures
risks
risk
factors
detailed
public
filings
us
securities
exchange
commission
including
recently
filed
annual
report
form
filed
sec
except
otherwise
noted
statements
speak
date
press
release
undertake
obligation
update
revise
statements
reflect
events
circumstances
occurring
press
release
caution
investors
place
considerable
reliance
statements
contained
press
release
information
investor
contact
peter
vozzo
westwicke
media
contact
